http://www.globalwatchservice.com/pages/TwoColumns.aspx?PageID=439&ProfileID=1010&UseRef=False

Heres a recommendation from Hoods mind you since then ERX has had a bit of dilution, but i would not say no to 7.75p

hurry hurry hurry.. news could be out any day

You can get a job at the fair otherwise selling the rides!

ok last chance, really is!!! your iether in or your out

Sorry PH, ITS DRIVERS FAULT he told me how to do it !! cant stop now !! but good luck for next week : )

PH anything happening?

25th.. put it in ya diary

EiRx Therapeutics (EiRx)



Announces Triggering of First Success Milestone Payments with OSI
Pharmaceuticals for the License of EiRx's Apoptosis Drug Targets



EiRx Therapeutics plc ("EiRx"). (LSE:AIM: ERX), the healthcare company
specialising in the control of programmed life and death of cells (apoptosis) is
pleased to announce its first major milestone agreement since its flotation on
AIM earlier this year with a potential value of up to US $18.8 million.



Following a 12 month period of Evaluation and Option, OSI Pharmaceuticals
("OSIP"), has elected to licence and take forward four of EiRx's novel
apoptosis gene targets into drug discovery for oncology. OSI Pharmaceuticals
(headquartered in Melville, NY), is a leading biotechnology company focused on
the discovery, development, and commercialization of high-quality, next-
generation oncology products. A success fee for each target is payable by OSIP,
as part of a deal consisting of upfront access and consultancy fees, potential
success fees for each target elected by OSIP to license and potential milestone
payments based on successful commercialisation of a novel therapeutic with
respect to each such target.



Ian Hayes, Ph.D., Chief Executive Officer of EiRx Therapeutics plc., commented:
"We are delighted by this positive outcome, to the therapeutic evaluation of our
novel apoptosis gene targets, by OSIP. Apoptosis regulation is rapidly gaining
appreciation as a central factor for many diseases, not least cancer. In
additional to the further validation of EiRx's apoptosis gene target discovery
platform ALIBI(TM), our agreement provides the opportunity to rapidly develop some
of EiRx's proprietary targets for drug discovery, while working with - and
learning from - one of the global leaders in developing novel oncology products."



"Our initial collaboration with EiRx has been very productive and we are excited
to be moving to the next phase of this research in which we will evaluate the
potential of the targets for the discovery of small molecules capable of
inducing apoptosis," stated Neil Gibson, Ph.D., Vice President of Research at
OSI Pharmaceuticals, Inc.

potatohead who posted this news as i cannot find it ?

its an rns

OSI Pharmaceutical Starts New Tarceva Lung Cancer Trial
Thursday September 21st, 2006 / 13h48


DOW JONES NEWSWIRES
OSI Pharmaceuticals Inc. (OSIP) said it will start a Phase III study of its Tarceva drug as a targeted adjuvant treatment for certain non-small-cell lung-cancer patients who have undergone surgery.
The Melville, N.Y., drug developer said the once-daily medication is currently indicated for patients with non-small-cell lung cancer who did not respond to at least one round of chemotherapy and for some types of pancreatic cancer when used in combination with a specific type of chemotherapy.
OSI, which is developing the drug in concert with Genentech Inc. (DNA) and Roche Holding AG (RHHBY), said the study will enroll 945 patients in different locations around the world.
The study also will examine whether testing for a specific type of component in tumor tissue can help identify patients more receptive to treatment, OSI said.
-James DeWeese; 201-938-5400; AskNewswires@dowjones.com

It's not showing as an RNS in the UK?

oh yes it is

http://www.advfn.com/p.php?pid=nmona&cb=1161601588&article=7553880&symbol=LSE%3AERX

Found it at advfn on your link but not on any other site yet! Including London stock exchange

blimey... its from 2004.. I am merely pointing out we are now due 19mil from them

as well as the 19mil for the breast cancer deal

keep up!!!

PH not funny it's dated from your input so people will read it as such!
ADVFN for me cuts out after a few seconds so I didn't read the dates.
We know good news is coming just think before you put up a link without dating it!

PH can you put it bullet notes all the things expected and rough time scales?

Press Release News | Home

Researchers Advancing Blood Cancer Therapies Receive $42.75 Million in Grants From The Leukemia & Lymphoma Society
Posted on : Mon, 23 Oct 2006 11:04:00 GMT | Author : The Leukemia & Lymphoma Society
News Category : PressRelease


WHITE PLAINS, N.Y., Oct. 23 /PRNewswire/ -- The Leukemia & Lymphoma Society today announced it has awarded four new Specialized Center of Research (SCOR) grants, the Society's most ambitious and synergistic research initiative, bringing the program's total funding to $159 million since its inception in 2000.

Three of this year's SCOR recipients will receive $1.25 million per year for five years, for a total of $6.25 million, and one will receive $1.05 million per year for five years, for a total of $5.25 million. In addition, the Society is renewing three existing SCORs for five more years.


The innovative SCOR program brings together teams of researchers representing different disciplines in a collaborative effort to discover new approaches to treat patients with leukemia, lymphoma or myeloma. Awards go to those groups that best demonstrate outstanding scientific promise and the synergy that will occur from their combined efforts.

"The four SCOR recipients selected this year have assembled teams that are pursuing new targets for drug therapy," said Marshall Lichtman, M.D., the Society's executive vice president, Research & Medical Programs. "In addition to lymphoma, acute myelogenous and lymphocytic leukemia, two understudied problems, infant leukemia and the myeloproliferative diseases are being investigated. The latter diseases are essentially three different forms of chronic myelogenous leukemia. A recently described mutation common to the myeloproliferative diseases provides an opportunity to develop the first specific treatment of these disorders. These SCOR grants represent an impressive addition of outstanding scientists and scientific goals to the Society's Specialized Centers program."

The recipients for 2006 are:

Frederick W. Alt, PhD., Howard Hughes Medical Investigator at Children's Hospital Boston; Janeway Professor of Pediatrics and Professor of Genetics at Harvard Medical School; Scientific Director of the CBR Institute for Biomedical Research. Dr. Alt received the Society's de Villiers International Achievement Award last year for his seminal work in immune cell function, genetic instability in cancer, and the DNA repair process that can prevent cancer-causing mutations. His SCOR will focus on the causes of B cell lymphomas and the development of new therapies for these tumors. To develop more effective treatments, Dr. Alt's team will focus on two fundamental properties of malignant B cells: B cell receptor (BCR) signaling and DNA repair-associated genetic abnormalities. They will identify pre-disposing genetic factors that are likely to serve as molecular targets for new therapies. The SCOR team also includes researchers from Dana-Farber Cancer Institute.

Carolyn A. Felix, MD, Children's Hospital of Philadelphia; Professor of Pediatrics at the University of Pennsylvania School of Medicine. Dr. Felix's research concentrates on improving the dismal outcome for infants with leukemia -- these blood cancers are characterized by chromosomal abnormalities called translocations which involve the breakage and abnormal recombination of a gene called MLL (Mixed Lineage Leukemia) with one of many partner genes. Dr. Felix's SCOR team will characterize the MLL leukemia stem cell from which all other leukemia cells derive, identify and develop agents that specifically target cells with MLL translocations, and learn in which infants these new drugs are most likely to be effective. Her team comprises researchers from the University of New Mexico Health Sciences Center, the Sidney Kimmel Comprehensive Center at Johns Hopkins University, Stanford University and Tulane University. The multi-faceted, multi-institutional team will collaborate with and access critical resources of the Children's Oncology Group in order to streamline advancement of new agents from the laboratory to affected infants.

Anthony Green, MD, PhD, FRCPath, University of Cambridge, Cambridge Institute for Medical Research Haematology. Prof. Green studies normal hematopoietic stem cells and the way they can give rise to haematological malignancies including the myeloproliferative disorders (MPDs). Research has shown that defects in one gene, JAK2, are present in most but not all patients with an MPD. This and other molecular discoveries will help develop new approaches to the diagnosis and treatment of these disorders. Prof. Green's SCOR, based in the United Kingdom, will bring together and provide infrastructural support for researchers from the Cambridge Institute of Medical Research, the MRC Laboratory of Molecular Biology, the Sanger Institute and Addenbrooke's Hospital. The SCOR will also benefit from Prof. Green's role as coordinator of the largest randomized MPD clinical trial and from collaboration with the UK MPD Study Group, a national network of MPD physicians.

Michael Thirman, MD, Associate Professor of Medicine and Director of Leukemia Biology, University of Chicago. Dr. Thirman's work is focused on critical genetic changes in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). His SCOR will develop and test novel agents that can target and disrupt the molecular pathways that result in the transformation of blood cells into cancer cells. The researchers will study the role of several genes that are critical to the development of leukemia and lymphoma. They will focus on the development of peptides and small molecules that can penetrate cancer cells and target pathways that are essential to survival. His SCOR is a collaboration with researchers from the University of Chicago, Albert Einstein College of Medicine in New York, and University of California San Diego.

In addition to the four new centers, the Society has renewed three SCORs led by Carl June, MD, University of Pennsylvania, whose SCOR is working on developing new immunotherapies for adults and children with blood cancers; Stephen Nimer, MD, Memorial Sloan-Kettering Cancer Center, whose team is working toward understanding how fusion proteins cause leukemias and might serve as new therapy targets; and Jerry Adams, PhD, Walter & Eliza Hall Institute of Medical Research, whose SCOR is trying to understand how the cell death process called apoptosis is blocked in blood cancer cells so that new, targeted drugs can be developed to effectively kill cancer cells.

SCOR is one of three integrated research programs established by the Society. The Career Development Program provides stipends to investigators of exceptional promise in the early stages of their careers, and the Translational Research Program encourages and supports outstanding investigative research that shows strong promise of translating biomedical knowledge into new treatments. The Society also bestows the Stohlman Scholar Award, given to scientists who hold faculty-level or equivalent positions at major research institutions and who are in the fifth year of their research.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 66 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $483 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 4.2 million contacts with patients, caregivers and healthcare professionals.

Short version what is good for us?